Hey dimwit… your drug is a 9000 first year money crap by Novartis. You are sticking it to Medicare which in turn sticks it to the American tax payer. Wake up. And yes outcomes matter. And yes long term safety matters. The mechanism is intracellular genetic process. So shut it. Have you read the ACC consensus statement or you just blindly dumb as you sound
-
Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page
Leqvio is a failed drug
- Thread starter anonymous
- Start date
-
- Tags
- None
Comical.
1) The 1st yr annualized cost will be more then $9k. $9k/yr/person is far cheaper than a lot of other governmental waste.
2) $9k drug is CHEAP when you compare it to other medical benefit biologics.
3) You do NOT work for the Nazis in any capacity, and you absolutely are not on the Leqvio Sales side.
4) Those on the Leqvio sales side are incentives on Leqvio, and most will try to get as many Leqvio orders/RXs fulfilled as possible.
5) You should speak to a few cardiologists who have actually ordered Leqvio and hear what tbiological.
6) Speak to patients who are taking the PCSK9s and ask if they would like 2x/month or 2xs/yr. Don't forget to tell them that 2xs/yr doesn't contribute to ther donut hole, unlike 2xs/month drug.
6) People do things for their own self interest, if you haven't figure that out yet.
7) Report back when you complete #5 & #6.
I withdrew my AD application and then got an offer external. I couldn't do it anymore. Every call, every meeting with leadership, pushed me further and further away. I don't see a future in cv at Novartis - if you take the ADAR role, I think you'll be looking again within 9-12 months. And not sure you'll be eligible for a role in another Novartis division if you have to be in role for a certain amount of time blah blah blah. I put notice in and won't even be able to collect the package but I don't care. I'm running.
Smart move. I shake my head at anyone who’s going after these jobs. It’s a dead end!
you sound like a typical, uninformed, brainwashed pharma rep. Your drug is nothing but a Medicare tax payer money grab by Novartis - at the expense of patients. Why do you say 2x per year when the first year is 3x year? Do patients know this ties them down to an infusion center or mandatory office visit along with all of the things going on in their life? You could give a s… about patients. Have you read the ACC Consensus Statement? You are the reasons doctors run from pharma reps.
8. Report back to me with outcomes
Smart. Run as far from Novartis CV as you can,
Just move the fuck on with your external company if that’s your choice, but don’t act like those people have done anything to you.
you should absolutely run if you’re the type of person who seeks advice on cafepharma, sure you had great parents to teach you how to make grown up decisions
Outcomes data are critical.
NVS acquired inclisiran (Leqvio) for $9.7 BILLION three and a half years ago, yet there is no evidence that taking Leqvio reduces the risk of myocardial infarction, stroke, coronary revascularization, and CV deaths (outcomes).
With only a pharmacologic effect of lowering LDL cholesterol without clinical meaningfully outcomes, it's not surprising that sales of Leqvio are very low (almost negligible) regardless of the cost of the drug to patients, frequency of administration, or the number of sales reps and meetings
“The great Medicare money grab” by a sleeze ball company.
Bullshit.
Leqvio is, and will remain, in the tank because it is extremely difficult to pull-through.
Incompetence at every level.
The easiest acquisition pathway, AIC, is the one they bitch about incessantly and refuse to track properly.
I have lipidologists' who don't give a fuck about the lack of outcomes data because they have functional grey-matter and understand how well it works.
The problem that this product will never overcome is the company that owns it.
Commercial and some Medicare Advantage plans are the Achille's Heel, due to PCSK9 requirement. Few actually fail thisnl therapy.
The injectable cholesterol market was only worth barely over $1B when it was only Repatha & Praluent. Add a 3rd player to the scene and how much did Cpt Kwik-E-Mart pay for this drug?
Destined for failure. This is before the oral PCSK9s come, which will make everything worse for all 3 injectable cholesterol drugs.
The injectable cholesterol market was only worth barely over $1B when it was only Repatha & Praluent. Add a 3rd player to the scene and how much did Cpt Kwik-E-Mart pay for this drug?
Destined for failure. This is before the oral PCSK9s come, which will make everything worse for all 3 injectable cholesterol drugs.
I agree with this assessment.
In buying Leqvio for $9.7 billion, Vas wanted to play the long game but with each passing quarter where sales are in the approx. $20 to $50 million range, I don’t see how NVS is ever going to make up for the cost of acquiring this drug.
For Leqvio with an incomplete indication and with the two established competitors and more to come including oral PCSK9 inhibitors, to blame sales reps and layoff some of them is bad leadership and management.
Outcomes are key especially all competitor classes have heaps of it.
The adherence angle is not enough